Israel - Hebrew - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 10000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israel - Hebrew - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israel - Hebrew - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israel - Hebrew - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

Israel - Hebrew - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 8000 iu / 0.8 ml - erythropoietin

Israel - Hebrew - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

Israel - Hebrew - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Israel - Hebrew - Ministry of Health

medison pharma ltd - somatropin 5 mg / 1 ml - solution for injection - somatropin - 1. long-term treatment of children with growth failure due to inadequateendogenous growth hormone secretion.2. long-term treatment of growth failure associated with turner syndrome. 3. treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. 4. replacement of endogenous growth hormone in adults with growth hormone deficiency or either childhood or adult-onset etiology. growth hormone deficiency of either childhood or adult-onset etiology. growth hormone deficiency should be confirmed appropriately prior to treatment.

Israel - Hebrew - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - תמיסה לאינפוזיה - zidovudine 200 mg / 20 ml - zidovudine - zidovudine - retrovir iv for infusion is indicated for the short term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immuno deficiency syndrome (aids) or aids related complex (arc) who are unable to take retrovir oral formulations.

Israel - Hebrew - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows:• recent mi, recent stroke or established peripheral arterial disease: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi), recent stroke or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not) and other vascular death.• acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction), in combination with asa in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg clopi